---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019669"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:08:08.631960+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# RxSight Q1 revenue $17.5M (+96% YoY); raises FY2023 revenue and margin guidance

## Summary
- Revenue $17.5M, up 96% YoY; gross margin improved to 59% from 42%.
- Net loss $(13.2)M ($0.42/share) vs $(17.6)M loss a year ago; adjusted loss $(0.31)/share.
- LAL procedure volumes 10,523 (+153% YoY); LDD installed base grew to 456 units (+85% YoY).
- Raised ~$64.5M net proceeds from equity offerings; cash & investments $153.9M.
- FY2023 guidance raised: revenue $79-84M (prior $78-83M); gross margin 56-58% (prior 52-54%).

## SEC filing metadata
- accession: 0000950170-23-019669
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017023019669/0000950170-23-019669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017023019669/rxst-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019669
- JSON: https://secwatch.observer/filing/0000950170-23-019669.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019669.txt

## Key facts
- Earnings Releases
  RxSight, Inc. reported first quarter 2023 results: revenue 17.5 million, net income (13.2) million, EPS (0.42).
  - Period: first quarter 2023
  - Revenue: 17.5 million
  - Net income: (13.2) million
  - EPS: (0.42)
  - Result: reported results
  source text: In the first quarter of 2023, total revenue was $17.5 million, an increase of 96% compared to $8.9 million in the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1111485/000095017023019669/0000950170-23-019669-index.htm
- Earnings Releases
  RxSight, Inc. reported first quarter 2023 results: revenue 17.5 million, net income (13.2) million, EPS (0.42).
  - Period: first quarter 2023
  - Revenue: 17.5 million
  - Net income: (13.2) million
  - EPS: (0.42)
  - Result: reported results
  source text: following cataract surgery, today reported financial results for the three months ended March 31, 2023. Key Quarterly Highlights • Reported first quarter 2023 revenue of $17.5 million, an increase of 96% compared to the first quarter of 2022, reflecting: • The sale of 56 Light Delivery Devices (LDDTMs), representing a 40% increase in unit sales compared to the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1111485/000095017023019669/0000950170-23-019669-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.